logo

Summit Therapeutics Plc (SMMT)



Trade SMMT now with
  Date
  Headline
6/5/2018 7:11:49 AM Summit Therapeutics Q1 Loss £5.8 Mln Loss Of £4.8 Mln Last Year
4/19/2018 7:08:02 AM Summit Completes Dosing Of Ezutromid In PhaseOut DMD Clinical Trial
4/11/2018 7:07:23 AM Summit Therapeutics FY Loss £7.1 Mln Vs Loss £21.4 Mln Last Year
3/27/2018 7:07:48 AM Summit Therapeutics Unveils Placement Of £15 Mln Of Ordinary Shares To Investors In Europe
3/13/2018 7:12:07 AM Summit Therapeutics Announces Discovery Of Series Of Antibiotic Compounds That Kill Gonorrhoea Bacteria
3/7/2018 7:03:55 AM Summit Expands Enrolment In PhaseOut DMD Phase 2 Clinical Trial To Include Planned Additional Group
12/27/2017 2:21:30 AM Summit Therapeutics Obtains New Antibiotic Discovery And Development Platform Through Its Acquisition Of Discuva
12/21/2017 2:07:23 AM Summit Enters Into Licence And Commercialisation Agreement With Eurofarma For Latin American Rights To Ridinilazole
12/6/2017 7:10:15 AM Summit Therapeutics Q3 Revenue £1.7 Mln Vs. £0.6 Mln Prior Year
11/6/2017 9:30:38 AM Summit Signs Revenue Sharing Agreement With The Wellcome Trust For CDI Antibiotic Ridinilazole
9/13/2017 11:04:36 PM Summit Therapeutics Announces Pricing Of Public Offering Of 1.50 Mln ADSs At $12.00/ADS
9/11/2017 7:08:20 AM Summit Gets BARDA Contract Worth Up To $62 Mln To Support Development Of Ridinilazole For C. Difficile Infection
9/5/2017 7:12:19 AM Summit Reports Data From Phase 2 Trial Supporting Ridinilazole As Highly Selective Antibiotic For The Treatment Of CDI